Astrocytes are the most abundant glial cells and are involved in several functions critical for preservation of brain homeostasis. The change of astrocyte function and morphology (reactive astrogliosis) is a common pathological feature in many neurological disorders. Reactive astrocytes overexpress monoamine oxidase B (MAO-B) and molecular neuroimaging studies have employed MAO-B PET as surrogate markers of reactive astrogliosis. 18F-SMBT-1 is a novel PET tracer that selectively binds with high contrast to overexpressed MAO-B in reactive astrocytes (Harada et al. 2021). This tracer will provide robust measures of reactive astrogliosis in vivo and establish its relationship to misfolded protein aggregates.
Harada R, Hayakawa Y, Ezura M, Lerdsirisuk P, Du Y, Ishikawa Y, Iwata R, Shidahara M, Ishiki A, Kikuchi A, Arai H, Kudo Y, Yanai K, Furumoto S, Okamura N. 18F-SMBT-1: A selective and reversible positron-emission tomography tracer for monoamine oxidase-B imaging. J Nucl Med. 62(2): 253-258 (2021)
Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, Burnham S, Krishnadas N, Bozinovski S, Huang K, Lopresti BJ, Yanai K, Rowe CC, Okamura N. First-in-human evaluation of 18F-SMBT-1, a novel 18F-labeled MAO-B PET tracer for imaging reactive astrogliosis. J Nucl Med. (2022) (in press)
Villemagne VL, Harada R, Dore V, Furumoto S, Mulligan R, Kudo Y, Burnham S, Krishnadas N, Bourgeat P, Xia Y, Laws S, Bozinovski S, Huang K, Ikonomovic MD, Fripp J, Yanai K, Okamura N, Rowe CC. Assessing reactive astrogliosis with 18F-SMBT-1 across the Alzheimer’s disease spectrum. J Nucl Med. (2022) (in press)